Human CCL19 Protein

<strong>Human CCL19 Protein</strong>_x000D_ <strong>Catalog number:</strong> B2011838_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 0.5 mg/mL_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20 °C_x000D_ <strong>Keywords:</strong> CKb11 protein, ELC protein, MIP-3b protein, MIP3B protein, SCYA19 protein, C-C motif chemokine 19 protein, Beta chemokine exodus 3 protein, C C chemokine ligand 19 protein, CC chemokine ligand 19 protein, CCL19 protein, Chemokine (C C motif) ligand 19 pro_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models Cancer Immunol Immunother. 2021 Sep;70(9):2503-2515._x000D_ 2: Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, Li T, Liang B, Zhang J, Cao B, Liu M, Feng Y, Ye X, Chen X, Wang L, Tian Y, Li H, Li J, Hu H, He J, Hu Y, Zhi C, Tang Z, Gong Y, Xu F, Xu L, Fan W, Zhao M, Chen D, Lian H, Yang L, Li P, Zhang Z. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin J Hematol Oncol. 2021 Jul 29;14(1):118._x000D_ 3: Salem A, Alotaibi M, Mroueh R, Basheer HA, Afarinkia K. CCR7 as a therapeutic target in Cancer Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188499._x000D_ 4: Xu Z, Zhu C, Chen C, Zong Y, Feng H, Liu D, Feng W, Zhao J, Lu A. CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer Cell Death Dis. 2018 Sep 24;9(10):974._x000D_ 5: Mourcin F, Verdière L, Roulois D, Amin R, Lamaison C, Sibut V, Thamphya B, Pangault C, Monvoisin C, Huet S, Seffals M, Baulande S, Mechta-Grigoriou F, Legoix P, Rossille D, Guirriec M, Léonard S, Cartron G, Salles G, Fest T, Tarte K. Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape Immunity. 2021 Aug 10;54(8):1788-1806.e7._x000D_ 6: Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance Nat Rev Immunol. 2008 May;8(5):362-71._x000D_ 7: Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, Xu X, Wang C, Zhao S, Lv L, Long J, Lin D, Zhao A, Fang B, Jiang J, Tang S, Gao J. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma Front Immunol. 2021 Mar 5;12:609421._x000D_ 8: Wang Z, Pan L, Guo D, Luo X, Tang J, Yang W, Zhang Y, Luo A, Gu Y, Pan Y. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma Cancer Med. 2021 Jun;10(11):3808-3821._x000D_ 9: Lewandowski EM, Kroeck KG, Jacobs LMC, Fenske TG, Witt RN, Hintz AM, Ramsden ER, Zhang X, Peterson F, Volkman BF, Veldkamp CT, Chen Y. Structural Insights into Molecular Recognition by Human Chemokine CCL19 Biochemistry. 2022 Mar 1;61(5):311-318._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/27451948">10: Hwang H, Shin C, Park J, Kang E, Choi B, Han JA, Do Y, Ryu S, Cho YK. Human breast cancer-derived soluble factors facilitate CCL19-induced chemotaxis of human dendritic cells Sci Rep. 2016 Jul 25;6:30207. </a>_x000D_ _x000D_ <strong>Products Related to Human CCL19 Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>